Novartis announced that Tracy Furey was appointed as Head, US Corporate Communications. Furey takes on this role in addition to her current responsibilities as Head, Global Oncology Communications and Patient Advocacy.
n this expanded role, she will become a member of the US Country Leadership Team (CLT) and will partner with US business communications leads, Government & Public Affairs, and the Communications Leadership Team to enhance and protect the Novartis reputation in the US. In this role, she will also be instrumental in accelerating the Novartis culture movement and build a stronger sense of community among our US- based associates in partnership with the People & Organization function.
“Tracy is a highly experienced and respected communicator and patient advocacy leader. She is trusted by leaders and peers, agile, and driven to help make a difference for the patients we serve,” said Michael Willi, Group Head Communications and Advocacy. “She is known for building high performing teams and championing the values and behaviors that define our culture.”
Since joining Novartis in 2011, Furey has made important contributions across various roles in the company. First as Vice President, US Oncology Public Affairs & Communications where she led the policy, patient advocacy and access, and communications functions. Most recently as the Head of Novartis Oncology Communications and Advocacy (NOCA), Tracy leads the public relations, patient advocacy, content and internal communications, as well as social and traditional media for the Global Novartis Oncology business.
In this expanded role, Furey continues to report to Susanne Schaffert, CEO Novartis Oncology, and Willi. In addition, she will also report to Tom Kendris, President, Novartis Corporation and US Country President.